Daily Newsletter

07 August 2023

Daily Newsletter

07 August 2023

UK opens vaccine centre to bolster pandemic preparedness

The key focus of the centre will be on pathogens for which there exist no vaccines or for which vaccines are not regulated in the country.

Vishnu Priyan August 07 2023

The UK Health Security Agency (UKHSA) has opened a vaccine development and evaluation centre (VDEC) to globally bolster pandemic preparedness.

Located at the Porton Down site of the UKHSA, the facility is spread over 2,800m² of laboratory space.

The centre will have more than 200 scientists, who will work on almost 100 projects.

VDEC will facilitate the development of new vaccines by testing and assessing them against a range of threats that can lead to a health emergency. 

The facility will operate throughout the vaccine lifecycle, from product design to the assessment of effectiveness with the emergence of new variants.

The key focus will be on pathogens for which there currently exist no vaccines, or for which vaccines are not regulated in the UK, including avian influenza and monkeypox.

VDEC is said to be capable of delivering new vaccines within 100 days of detecting a new threat.

UKHSA chief executive professor Dame Jenny Harries stated: “VDEC is a unique facility in the UK, delivering multiple critical early pre and post-clinical research and evaluation studies in a single research facility. 

“This essential work will lead the way over the coming years in our fight against potentially deadly pathogens, further enhancing the UK’s credentials as a global science superpower.

“As well as building on the legacy of the pandemic caused by Covid-19, VDEC will target a wide range of other deadly viruses and pathogens, helping to secure the health and prosperity of the UK and saving lives around the world.”

Healthcare companies are hesitant to invest in the metaverse

The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close